Holen Sie sich die Stockscreener-App
18.02
1.64%
0.29
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
Bausch + Lomb Corporation (BLCO) Investor Outlook: Eyeing a 3.24% Upside Amid Diverse Global Operations - DirectorsTalk Interviews
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb stock rises on survey-driven dry eye focus - AD HOC NEWS
Why Bausch + Lomb Corp stock is gaining today - Wealth Awesome
Bausch + Lomb study shows enVista Aspire lenses improve vision By Investing.com - Investing.com Canada
Bausch + Lomb study shows enVista Aspire lenses improve vision - Investing.com
Every patient in the study reached mid-range vision after cataract surgery. - Stock Titan
Does Advancing First-in-Class Dry Eye and Pain Drugs Change The Bull Case For Bausch + Lomb (BLCO)? - simplywall.st
Is Bausch + Lomb (TSX:BLCO) Strengthening Eye Care Leadership? - Kalkine Media
Bausch + Lomb Corporation - Menafn
Bausch + Lomb Survey Finds 14% Link Dry Eye to Menopause | BLCO Stock News - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing a 9.10% Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - Yahoo Finance
H.C. Wainwright reiterates Bausch & Lomb stock rating on pipeline data - Investing.com
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack - Yahoo Finance
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - TradingView
Bausch + Lomb eye drop cut pain duration from 37.8 seconds to 1.6 - Stock Titan
Trading (BLCO) With Integrated Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine - Seeking Alpha
Did Bausch + Lomb’s (BLCO) Board Overhaul Amid Weak Returns Just Shift Its Investment Narrative? - simplywall.st
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 9.24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Director Robert J. Chersi Granted 11,776 RSUs Under 2022 Incentive Plan - Kalkine Media
Bausch & Lomb (BLCO) director Barbara Trebbi receives 11,776-share RSU award - Stock Titan
Bausch & Lomb (BLCO) files Form 3 for new director Barbara Trebbi - Stock Titan
Bausch & Lomb (BLCO) director awarded 11,776 RSU-based common shares - Stock Titan
Bausch & Lomb (BLCO) director receives 11,776 RSU equity grant as compensation - Stock Titan
Bausch & Lomb Corp (BLCO) adds director Robert J. Chersi in Form 3 filing - Stock Titan
Bausch & Lomb Corp (BLCO) director Thomas Appio reports holding 27,583 shares - Stock Titan
Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics? - Kalkine Media
Senior VP Of Bausch + Lomb Sold 54% Of Their Shares - Moomoo
Bausch + Lomb (NYSE:BLCO) CAO Sells 52,900 Shares - marketbeat.com
Bausch & Lomb (BLCO) SVP Frederick Munsch sells 52,900 shares in August trade - Stock Titan
Is Bausch + Lomb’s Raised 2026 Outlook And Board Refresh Altering The Investment Case For BLCO? - simplywall.st
Form 8K Bausch & Lomb Corp For: 12 August By Investing.com - Investing.com South Africa
Bausch & Lomb Corp (BLCO) Director Andrew C. von Eschenbach Sells 18,559 Shares - GuruFocus
BLCO (BLCO) shareholder plans NYSE sale of 52,900 restricted shares - Stock Titan
Bausch + Lomb (NYSE:BLCO) Director Eschenbach Andrew Von Sells 12,500 Shares - MarketBeat
Bausch & Lomb (NYSE: BLCO) director sells 18,559 shares after board exit - Stock Titan
Insider Selling: Bausch + Lomb (NYSE:BLCO) Director Sells $100,458.22 in Stock - MarketBeat
BLCO | Bausch + Lomb Corporation FinancialsIncome Statement - Quiver Quantitative
BLCO shareholder plans $887,885 stock sale (NYSE: BLCO) - Stock Titan
Bausch + Lomb Corporation (BLCO): Growth Potential and Analyst Ratings Point to an 11% Upside - DirectorsTalk Interviews
Bausch + Lomb Updates Board, Reaffirms 2026 Guidance - VisionMonday.com
Bausch + Lomb Corporation $BLCO Shares Bought by Sei Investments Co. - marketbeat.com
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bausch Lomb (BLCO) investor plans sale of 12,500 common shares - Stock Titan
Bausch & Lomb Corp (BLCO) awards 16,778 performance-based shares to executive - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP earns PSUs for 9,091 shares - Stock Titan
Bausch & Lomb Corp (BLCO) EVP awarded 20,973 PSUs after targets met - stocktitan.net
Bausch & Lomb (NYSE: BLCO) CFO granted 50,335 performance-linked shares - Stock Titan
Bausch & Lomb (NYSE: BLCO) Surgical president earns 16,778-share PSU-based award - Stock Titan
Bausch & Lomb (NYSE: BLCO) CLO earns 33,557 performance-based shares - Stock Titan
Bausch & Lomb Corp (BLCO) CEO granted 281,879 PSUs tied to 2027 vesting - Stock Titan
Bausch & Lomb Corp SEC Filing (Aug 6, 2026) - Stock Titan
Bausch + Lomb appoints four directors, reaffirms 2026 guidance By Investing.com - Investing.com South Africa
Bausch Health CEO joins Bausch + Lomb board of directors By Investing.com - Investing.com South Africa
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Form 8K Bausch & Lomb Corp For: 6 August By Investing.com - Investing.com Nigeria
0.36%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):